MiNK Therapeutics, Inc. (INKT)

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Christine M. Klaskin - Treasurer and Principal Financial & Accounting Officer Jennifer S.

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs.

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy

MiNK Therapeutics, Inc. INKT stock is trading higher on Friday, with a session volume of 20.2 million compared to the average volume of 7.5 million as per data from Benzinga Pro.

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.

Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Zack Armen - IR Jennifer Buell - President and CEO Christine Klaskin - Principal Financial and Accounting Officer Thiago Favano - Senior Director, Portfolio Operations Conference Call Participants Emily Bodnar - H.C. Wainwright Matt Phipps - William Blair Operator Thank you for standing by.

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the first quarter of 2025 and provided a business update highlighting continued clinical progress and strategic developments across its iNKT platform. The company will host a conference call and webcast today at 8:30 a.m. ET.

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q4 2024 Earnings Conference Call March 18, 2025 8:30 AM ET Company Participants Zack Armen - Investor Relations Dr. Jennifer Buell - President and CEO Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET.

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combination, botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastric cancer (NCT06251973).

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium in San Francisco, California.